Acetic Acid

證據等級: L5

預測適應症: 10 個

Acetic Acid: From Topical Antimicrobial to Post-Bacterial Disorder

One-Sentence Summary

Acetic acid is a well-established topical antimicrobial and acidifying agent, used clinically in wound irrigation, otitis externa management, and as a diagnostic aid (Visual Inspection with Acetic Acid, VIA) in cervical cancer screening programmes. The TxGNN model predicts it may be effective for post-bacterial disorder, with 18 clinical trials retrieved but no direct publications currently supporting this specific therapeutic direction. The overall evidence base is preclinical and mechanistically indirect; this candidate requires further investigation before any clinical translation.

Quick Overview

Item	Content
Original Indication	No SAHPRA-registered indication on record; known clinical use as topical antimicrobial/antiseptic agent
Predicted New Indication	Post-Bacterial Disorder
TxGNN Prediction Score	99.98%
Evidence Level	L4
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current Evidence Pack. Based on established pharmacology, acetic acid (CH₃COOH) exerts its primary antimicrobial effect by acidifying the local microenvironment to pH < 4.5, thereby disrupting bacterial membrane integrity, inhibiting key enzymatic pathways, and suppressing growth of a broad spectrum of Gram-positive and Gram-negative organisms — including Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli. It has additional capacity to disrupt bacterial biofilms, which is particularly relevant in chronic wound and ear canal infections. As a short-chain fatty acid (SCFA), acetic acid also participates in gut microbiome regulation, where it influences colonocyte metabolism, mucosal immunity, and intestinal pH homeostasis.

The predicted indication of “post-bacterial disorder” refers to sequelae arising after a primary bacterial infection has resolved — such as reactive arthritis, post-streptococcal glomerulonephritis, or post-infectious irritable bowel syndrome (PI-IBS). The conceptual link to acetic acid lies in two potential pathways: (1) residual bacterial clearance via the established antimicrobial mechanism, reducing the antigenic stimulus that drives immune-mediated sequelae; and (2) restoration of gut microbial homeostasis following infection-induced dysbiosis, through acetic acid’s role as an SCFA prebiotic.

However, it is important to note that most post-bacterial disorders are driven by immune complex deposition, molecular mimicry, or persistent inflammation — processes that acetic acid’s acidification mechanism cannot directly modulate. The TxGNN prediction likely reflects proximity of infection-related disease nodes within the knowledge graph rather than a validated pharmacological relationship. The mechanistic rationale, while not implausible, is indirect and requires experimental validation before clinical consideration.

Clinical Trial Evidence

No clinical trial directly investigates acetic acid as a therapeutic intervention for post-bacterial disorder. The trials below were retrieved by the evidence pipeline in this context; relevance grades are as assessed by the pipeline.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04120259	N/A	Completed	126	Only completed RCT with a direct acetic acid-containing intervention (Apple Cider Vinegar, 5–6% acetic acid, + Metformin vs. Metformin alone) in newly diagnosed Type 2 Diabetes. Provides safety and metabolic effect data for oral acetic acid administration; target indication is metabolic, not post-bacterial.
NCT03212729	N/A	Completed	10	Evaluated antimicrobial photodynamic therapy (aPDT) as adjunct to endodontic treatment for apical periodontitis caused by E. faecalis and Candida spp. Antimicrobial context only; acetic acid is not the intervention. Very small sample.
NCT04824261	N/A	Unknown	100	Compared 4% boric acid versus clotrimazole solution for otomycosis. Relevant as an acid-based antimicrobial ear canal strategy; boric acid is not acetic acid and results cannot be directly extrapolated.
NCT04036318	N/A	Completed	3,022	Large-scale presumptive periodic treatment (PPT) trial for STI prevention in high-risk populations in Tanzania. Provides epidemiological context on post-infectious bacterial burden in sub-Saharan Africa; intervention is not acetic acid.
NCT05710094	Phase 1	Completed	28	Safety and tolerability of SoftOx Biofilm Eradicator (SBE), a topically applied biofilm disruption agent for chronic leg wounds. Biofilm eradication is a mechanism shared with acetic acid; no direct acetic acid data.
NCT06612164	N/A	Completed	65	Evaluated health effects of kefir consumption (a fermented beverage containing trace organic acids including acetic acid) on gastrointestinal, immune, and biochemical parameters in healthy adults. Highly indirect relevance.
NCT06005506	N/A	Completed	64	Randomised trial of active versus passive synbiotic supplementation in chronically frail patients with altered intestinal function (ALS, ADHD, bronchial asthma). Gut microbiome context with indirect SCFA relevance.
NCT02872675	N/A	Completed	17	Prebiotic supplementation effect on gut bacterial SCFA metabolites and systemic inflammation markers in adults with exercise-induced bronchoconstriction. Very small sample; no direct acetic acid intervention.
NCT07386795	N/A	Not yet recruiting	19	Microbiota transplantation combined with prebiotics for functional constipation. Gut dysbiosis context; not yet recruiting and very small planned sample.
NCT07048028	N/A	Recruiting	90	Evaluates chitosan irrigation solution versus sodium hypochlorite/EDTA combinations for root canal bacterial clearance. Antimicrobial comparator context; no acetic acid arm.

Literature Evidence

Currently no related literature available for acetic acid in post-bacterial disorder.

South Africa Market Information

Acetic acid (DrugBank ID: DB03166) has no products currently registered with SAHPRA and is not available as an approved pharmaceutical on the South African market.

Dilute acetic acid preparations (e.g., 1–2% ear drops for otitis externa) may be used in clinical practice via compounding pharmacies or importation under Section 21 of the Medicines and Related Substances Act. Clinicians should verify current availability through the SAHPRA regulatory database. There is no Essential Medicines List (EML) entry for acetic acid as a standalone pharmaceutical.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for full safety information. No DrugBank-derived key warnings, contraindications, or drug interaction data were retrieved for this candidate. Report adverse drug reactions to SAHPRA via the MedSafety reporting system.

General note based on established pharmacology: Concentrated acetic acid (>25%) is corrosive and causes chemical burns. Dilute clinical preparations (0.25–5%) are generally well tolerated on intact skin and mucous membranes but may cause localised irritation, particularly on inflamed or denuded tissue. Oral administration in the form of undiluted apple cider vinegar has been associated with oesophageal erosion and dental enamel demineralisation at prolonged or high-concentration use. Systemic acid-base effects are negligible at typical clinical doses. The safety profile for systemic therapeutic use in post-bacterial disorder has not been established.

Conclusion and Next Steps

Decision: Hold

Rationale: Although the TxGNN model assigned a very high prediction score (99.98%), this likely reflects knowledge graph node proximity within the infection-related disease cluster rather than a direct pharmacological mechanism. Post-bacterial disorders are predominantly immune-mediated conditions that do not respond to antimicrobial acidification, and the retrieved evidence base contains no clinical trials or published literature directly investigating acetic acid in this indication. Acetic acid is also not currently registered in South Africa, adding a further regulatory barrier to clinical development.

To proceed, the following is needed:

Indication clarification: Define the specific post-bacterial entity to be targeted (e.g., reactive arthritis, PI-IBS, post-streptococcal nephritis), as each subtype carries a different mechanistic plausibility profile and evidence landscape
Mechanism of action data: Retrieve full DrugBank MOA record, including pharmacodynamics, targets, and SCFA pathway data relevant to gut immune modulation
Preclinical evidence: In vitro or animal model data demonstrating that acetic acid can modulate the immune-inflammatory pathways (e.g., complement activation, Th17/Treg axis) implicated in post-bacterial sequelae
Route of administration plan: Define the intended route (oral SCFA supplementation vs. topical/local application) and concentration, as safety and efficacy profiles differ substantially
SAHPRA regulatory pathway: If development proceeds, clarify the regulatory route for an unregistered compound targeting a new indication
Diagnostic vs. therapeutic distinction: If the envisaged application is as a diagnostic aid (VIA for post-infectious cervical lesions in HIV-positive women — as suggested by several retrieved trials), a separate diagnostic accuracy evidence review is warranted and may yield a more favourable evidence assessment

This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.